Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) EVP Jill Henrich sold 1,000 shares of the firm's stock in a transaction on Monday, November 18th. The stock was sold at an average price of $11.20, for a total transaction of $11,200.00. Following the transaction, the executive vice president now directly owns 19,378 shares in the company, valued at $217,033.60. The trade was a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Atara Biotherapeutics Stock Down 2.8 %
NASDAQ:ATRA opened at $10.68 on Thursday. Atara Biotherapeutics, Inc. has a 52 week low of $6.50 and a 52 week high of $39.50. The stock has a 50 day moving average of $9.14 and a 200-day moving average of $10.11.
Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, beating analysts' consensus estimates of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same period in the previous year, the company posted ($16.50) earnings per share. As a group, sell-side analysts anticipate that Atara Biotherapeutics, Inc. will post -12.12 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
I was wrong. Dead wrong.
From Porter & Company | Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was.
Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.
A number of institutional investors and hedge funds have recently bought and sold shares of ATRA. Point72 Asia Singapore Pte. Ltd. bought a new stake in Atara Biotherapeutics in the second quarter worth approximately $53,000. Cubist Systematic Strategies LLC acquired a new position in shares of Atara Biotherapeutics during the 2nd quarter valued at about $79,000. State Street Corp raised its stake in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company's stock valued at $182,000 after acquiring an additional 7,680 shares in the last quarter. FMR LLC lifted its holdings in Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company's stock worth $204,000 after purchasing an additional 7,381 shares during the last quarter. Finally, Delap Wealth Advisory LLC bought a new stake in Atara Biotherapeutics during the first quarter worth approximately $29,000. Hedge funds and other institutional investors own 70.90% of the company's stock.
Analyst Ratings Changes
Several brokerages recently issued reports on ATRA. Mizuho upgraded Atara Biotherapeutics from a "neutral" rating to an "outperform" rating and cut their price objective for the stock from $25.00 to $18.00 in a research report on Friday, August 16th. HC Wainwright restated a "neutral" rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. Finally, Canaccord Genuity Group lifted their target price on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $16.67.
Check Out Our Latest Stock Report on ATRA
Atara Biotherapeutics Company Profile
(
Get Free Report)
Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
